1737 — Taiyen Biotech Co Balance Sheet
0.000.00%
- TWD6.33bn
- TWD4.60bn
- TWD3.24bn
- 82
- 58
- 35
- 64
Annual balance sheet for Taiyen Biotech Co, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 1,891 | 2,084 | 1,887 | 1,840 | 1,938 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 541 | 758 | 650 | 663 | 498 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 2,900 | 3,395 | 3,094 | 3,026 | 2,927 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 3,431 | 3,564 | 3,713 | 3,907 | 4,025 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 7,798 | 8,468 | 8,212 | 8,320 | 8,381 |
Accounts Payable | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 695 | 1,305 | 926 | 1,101 | 1,165 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 1,568 | 2,106 | 1,690 | 1,829 | 1,717 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 6,229 | 6,361 | 6,521 | 6,491 | 6,664 |
Total Liabilities & Shareholders' Equity | 7,798 | 8,468 | 8,212 | 8,320 | 8,381 |
Total Common Shares Outstanding |